Journal
CHEMICAL SCIENCE
Volume 9, Issue 27, Pages 5957-5966Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c8sc01186a
Keywords
-
Categories
Funding
- AstraZeneca
- Engineering and Physical Sciences Research Council [EP/L505067/1]
Ask authors/readers for more resources
Cellular uptake of circulating cholesterol occurs via the low density lipoprotein receptor (LDLR). The E3 ubiquitin ligase IDOL is a mediator of LDLR degradation, with IDOL homodimerization thought to be required for its activity. To probe the possibility of modulating LDLR levels with an inhibitor of IDOL homodimerization, we screened a SICLOPPS library of 3.2 million cyclic peptides for compounds that disrupt this protein-protein interaction. We identified cyclo-CFFLYT as the lead inhibitor, and improved its activity through the incorporation of non-natural amino acids. The activity of the optimized cyclic peptide was assessed in hepatic cells, with a dose-dependent increase in LDLR levels observed in the presence of our IDOL homodimerization inhibitor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available